Solésence, Inc. (SLSN) Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Solésence, Inc. (formerly Nanophase Technologies Corporation) is a science-driven company focused on skin health and life sciences. The company rebranded in March 2025 and uplisted to the NASDAQ Capital Market (Symbol: SLSN) in April 2025. Its business is vertically integrated, offering engineered materials, formulation development, and commercial manufacturing for prestige skin care, cosmetics, and advanced materials.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $20,359 | $13,046 | $34,984 | $22,914 |
| Gross Profit | $5,877 | $3,740 | $9,259 | $7,320 |
| Gross Margin | 28.9% | 28.7% | 26.5% | 32.0% |
| Net Income | $2,667 | $856 | $2,747 | $1,747 |
| Diluted EPS | $0.04 | $0.01 | $0.04 | $0.03 |
| Cash & Equivalents | $4,108 | $2,358 (End Q2 2024) | $4,108 | $2,358 |
| Total Debt (Related Party) | $16,599 | $5,000 | $16,599 | $5,000 |
Note: All financial figures are in thousands, except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 56% year-over-year for the quarter and 53% year-over-year for the six-month period. This was driven primarily by a new significant customer in the consumer products category and increased sales of personal care ingredients.
- Profitability: Net income increased significantly, aided by a one-time gain from the Employee Retention Credit (ERC) program. Operating income improved due to higher sales volume, though gross margins were pressured by manufacturing inefficiencies and raw material costs.
- Debt Structure: The company significantly increased its reliance on related-party debt. Total borrowings from affiliates (Beachcorp, LLC and Strandler, LLC) rose from $5.0 million at year-end 2024 to $16.6 million as of June 30, 2025, to fund working capital and inventory growth.
- Cash Flow: Operating cash flow was negative ($7.875 million used) for the six months ended June 30, 2025, primarily due to a $6.18 million increase in accounts receivable and a decrease in deferred revenue. This was offset by financing activities providing $11.8 million in cash.
Guidance, Outlook, and Risks
- Strategic Focus: Management is prioritizing consumer products and skin health ingredients over legacy advanced materials. The company expects fixed manufacturing costs to be absorbed more efficiently as volume scales, potentially improving margins.
- Capital Expenditures: The company expects capital spending for 2025 to range between $1 million and $3 million, funded by operating profits and existing credit facilities.
- Key Risks:
- Customer Concentration: Three customers accounted for 73% of revenue in Q2 2025. Loss of a key customer would materially impact results.
- BASF Agreement: An exclusive supply agreement with BASF contains contingencies that could force the company to sell production equipment if performance requirements are not met.
- Related Party Dependence: A significant portion of debt is owed to affiliates of the company's controlling shareholder, creating potential conflicts or refinancing risks.
- ERC Contingency: While $1.234 million of ERC income was recognized, a reserve of $572,000 was established for potential IRS audits or discrepancies regarding the payment.
Investor Verification Checklist
- Verify the sustainability of the new customer contributing 27% of Q2 revenue and the terms of their supply agreement.
- Review the specific performance metrics in the BASF supply agreement that could trigger an equipment sale.
- Assess the company's ability to service the increased related-party debt ($16.6M) and the terms of the recent amendments extending maturities to 2027.
- Monitor the resolution of the $572,000 ERC liability reserve and potential future tax audits.
- Track the trend in gross margins as the company scales production to determine if manufacturing inefficiencies are being resolved.